Weinblatt M E
Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston 02115, USA.
Rheumatology (Oxford). 1999 Nov;38 Suppl 2:19-23.
Rheumatoid arthritis (RA) is a serious, chronic, debilitating disease for which no cure is available. Therapeutic aims for patients with RA are to alleviate symptoms, slow disease progression and optimize quality of life. In recent years, measures to achieve these goals have changed, and the development of new drugs will probably result in new treatment regimens. Two drugs with an extensive record of clinical experience are methotrexate and cyclosporin. Methotrexate is widely used because of its efficacy and high therapy retention rate. Both drugs have been shown to slow the progression of RA, but not without side-effects that sometimes preclude their use. As neither drug generally induces remission, improved treatments are needed. Combination therapy using drugs with different mechanisms of action is beginning to be evaluated, as are biological response modifiers targeted to specific mediators of the immune response. The future treatment of RA should provide more effective relief with fewer side-effects.
类风湿关节炎(RA)是一种严重的慢性致残性疾病,目前尚无治愈方法。RA患者的治疗目标是缓解症状、减缓疾病进展并优化生活质量。近年来,实现这些目标的措施已经发生了变化,新药的研发可能会带来新的治疗方案。两种拥有广泛临床经验记录的药物是甲氨蝶呤和环孢素。甲氨蝶呤因其疗效和高治疗保留率而被广泛使用。这两种药物都已被证明可以减缓RA的进展,但并非没有副作用,有时这些副作用会妨碍它们的使用。由于这两种药物一般都不能诱导缓解,因此需要改进治疗方法。使用具有不同作用机制的药物的联合治疗以及针对免疫反应特定介质的生物反应调节剂正在开始进行评估。RA的未来治疗应该在副作用更少的情况下提供更有效的缓解。